Targeting Metabolism in Triple-Negative Breast Cancer with p53 Changes
PRECISION METABOLIC THERAPY OF p53 MUTANT TRIPLE NEGATIVE BREAST CANCERS
This project looks for new ways to stop the growth of a specific type of aggressive breast cancer by focusing on its unique energy needs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11118927 on NIH RePORTER |
What this research studies
This research aims to find new ways to treat triple-negative breast cancer (TNBC) that has changes in the p53 gene, a common feature in this aggressive cancer. Researchers know that cancer cells have different energy needs than healthy cells, and they are exploring how to target these differences. By using a large-scale screening method, they found a specific enzyme, ASAH1, that appears crucial for the growth and spread of these p53-mutant TNBCs. They have also identified potential drug candidates that can block ASAH1, suggesting a new path for treatment.
Who could benefit from this research
Good fit: Patients with triple-negative breast cancer that has a p53 gene mutation would be the focus of future treatments developed from this research.
Not a fit: Patients with other types of breast cancer or those whose triple-negative breast cancer does not have a p53 mutation may not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this work could lead to new, targeted treatments for patients with p53-mutant triple-negative breast cancer, a form of cancer that currently lacks specific therapies.
How similar studies have performed: This research builds on the understanding that cancer cells have unique metabolic needs and has already identified specific targets and potential inhibitors, suggesting a promising, yet still early-stage, approach.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Gupta, Romi — University of Alabama at Birmingham
- Study coordinator: Gupta, Romi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.